The uroflowmetric parametres in patients taking alpha adrenergic
blockers have never been evaluated.
In March 2000, Synaptic began making non-exclusive licenses available to companies in need of Synaptic's portfolio of intellectual property on the alpha adrenergic
receptors for drug discovery.
1,2) Alpha adrenergic
receptor like [alpha]1A and [alpha]1D have been documented to be distributed the in the lower urinary tract and the distal ureter and the use of alpha adrenergic
receptor blockers like Tamsulosin have shown considerable promise in treating the stent related symptoms.
Phenylephrine is a sympathomimetic agent which acts primarily as an alpha adrenergic
In March of this year Synaptic began to make available non-exclusive licenses to its alpha adrenergic
and benign prostatic hypertrophy patents.
307 (14%) took alpha adrenergic
receptor blockers (-ARs).
6,7) The expectant approach by using alpha adrenergic
receptor antagonist for management of distal ureteric stones used as adjuvant medical expulsive therapy (MET), and be able to reduce symptoms and facilitate stone expulsion due to the presence of alpha and beta adrenergic receptors (AR) in the human ureter.
Synaptic Pharmaceutical Corporation (Paramus, NJ; 201-261-1331) announced that it has been awarded United States Patent 6,083,705 for the use of the alpha adrenergic
1D receptor to screen compounds that bind to it.
5%, an alpha adrenergic
receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
Exclusion criteria included the patients on alpha adrenergic
receptor blockers, local sepsis at the site of proposed puncture, patient with known hypersensitivity to study drug, patients being treated with anticoagulants, CNS active drugs, patients suffering from bleeding diathesis or coagulation disorders, spinal deformity or tuberculosis spine, increased intracranial pressure, patients with some psychiatric history, patients with neurological disease with motor and sensory deficit.